Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Yasuto Yoneshima, Isamu Okamoto, Tomotsugu Takano, Aimi Enokizu, Eiji Iwama, Taishi Harada, Koichi Takayama, Yoichi Nakanishi

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

元の言語英語
ページ(範囲)349-351
ページ数3
ジャーナルLung Cancer
88
発行部数3
DOI
出版物ステータス出版済み - 6 1 2015

Fingerprint

Therapeutics
Protein-Tyrosine Kinases
crizotinib
CH5424802
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

これを引用

Successful treatment with alectinib after crizotinib-induced esophageal ulceration. / Yoneshima, Yasuto; Okamoto, Isamu; Takano, Tomotsugu; Enokizu, Aimi; Iwama, Eiji; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi.

:: Lung Cancer, 巻 88, 番号 3, 01.06.2015, p. 349-351.

研究成果: ジャーナルへの寄稿記事

Yoneshima, Yasuto ; Okamoto, Isamu ; Takano, Tomotsugu ; Enokizu, Aimi ; Iwama, Eiji ; Harada, Taishi ; Takayama, Koichi ; Nakanishi, Yoichi. / Successful treatment with alectinib after crizotinib-induced esophageal ulceration. :: Lung Cancer. 2015 ; 巻 88, 番号 3. pp. 349-351.
@article{0534a36ac3d84ace924d1d169ab5c0d0,
title = "Successful treatment with alectinib after crizotinib-induced esophageal ulceration",
abstract = "Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.",
author = "Yasuto Yoneshima and Isamu Okamoto and Tomotsugu Takano and Aimi Enokizu and Eiji Iwama and Taishi Harada and Koichi Takayama and Yoichi Nakanishi",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2015.03.012",
language = "English",
volume = "88",
pages = "349--351",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Successful treatment with alectinib after crizotinib-induced esophageal ulceration

AU - Yoneshima, Yasuto

AU - Okamoto, Isamu

AU - Takano, Tomotsugu

AU - Enokizu, Aimi

AU - Iwama, Eiji

AU - Harada, Taishi

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

AB - Crizotinib was the first clinically available inhibitor of the tyrosine kinase ALK, and next-generation ALK inhibitors, such as alectinib, are now under development. Although crizotinib is generally well tolerated, severe esophageal injury has been reported as a rare but serious adverse event of crizotinib therapy. We now describe the successful treatment with alectinib of a patient who developed crizotinib-induced esophageal ulceration.

UR - http://www.scopus.com/inward/record.url?scp=84929506043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929506043&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.03.012

DO - 10.1016/j.lungcan.2015.03.012

M3 - Article

C2 - 25837798

AN - SCOPUS:84929506043

VL - 88

SP - 349

EP - 351

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -